Monday, 24th April 2017 17:15:40 GMT+0530
Ad Here

Current Partners

THSTI (Translational Health Science and Technology Institute) & Sphaera Pharma (India), a subsidiary of Sphaera Pharma (Singapore) have received funding from The Wellcome Trust to develop a novel, first-in-class, therapeutic for the treatment of multiple drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB). THSTI is a society formed by a galaxy of leading science administrators, registered with the Registrar of Societies, Govt. of NCT, Delhi. THSTI addressed public health issues of national priority through various niche research centers. Among those, six intramural centers with interdisciplinary focus, two extramural centers and one partnership center are functioning currently to meet its objectives of contemporary translational research.  
Sphaera Pharma and Cardero Therapeutics, a California based Biotech, are collaborating  to develop a class of compounds which target mitochondrial biogenesis and have demonstrated efficacy for the treatment of cardiovascular diseases and metabolic diseases.  The collaboration, initiated in 2010, seeks to exploit novel biology uncovered surrounding a natural product studied at Cardero which induces mitochondrial biogenesis. Through the collaboration the only commercial synthetic route to make this highly desirable natural product of interest has been discovered and developed, as well as novel leads addressing metabolic and CV diseases have been identified and are in development. The natural product has undergone several successful Phase I studies. It is currently in a Phase I/ IIa study for Muscular Dystrophy. Other related compounds are being staged for human clinical studies.
Sphaera Pharma and Synthia Dermatech entered into collaboration in the 2009 to develop Novel treatments for Neuropathic Pain that continues to be a high unmet medical need. Our collaboration is based on biology developed at Synthia and a concept co-developed by Sphaera.